Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-04-13
2009-10-06
Flood, Michele C. (Department: 1655)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07598275
ABSTRACT:
Methods are provided for induction of angiogenesis by administration of nicotine or other nicotine receptor agonist. Induction of angiogenesis by the methods of the invention can be used in therapeutic angiogenesis in, for example, treatment of ischemic syndromes such as coronary or peripheral arterial disease.
REFERENCES:
patent: 4725609 (1988-02-01), Kull, Jr. et al.
patent: 4946853 (1990-08-01), Bannon et al.
patent: 5069904 (1991-12-01), Masterson
patent: 5318957 (1994-06-01), Cid et al.
patent: 5508030 (1996-04-01), Bierman
patent: 5547965 (1996-08-01), Kruger et al.
patent: 5686448 (1997-11-01), Baldone
patent: 5700848 (1997-12-01), Soon-Shiong et al.
patent: 5770229 (1998-06-01), Tanihara et al.
patent: 5801033 (1998-09-01), Hubbell et al.
patent: 5804213 (1998-09-01), Rolf
patent: 5820583 (1998-10-01), Demopulos et al.
patent: 5827937 (1998-10-01), Agerup
patent: 5840693 (1998-11-01), Eriksson et al.
patent: 5844013 (1998-12-01), Kenndoff et al.
patent: 5853749 (1998-12-01), Hobbs
patent: 5866561 (1999-02-01), Ungs
patent: 5869037 (1999-02-01), Crystal et al.
patent: 6261279 (2001-07-01), Demopulos et al.
patent: 6264981 (2001-07-01), Zhang et al.
patent: 6417205 (2002-07-01), Cooke et al.
patent: 6610713 (2003-08-01), Tracey
patent: 6838471 (2005-01-01), Tracey
patent: 7160904 (2007-01-01), Cooke et al.
patent: 2002/0016344 (2002-02-01), Tracey
patent: 2002/0028798 (2002-03-01), Demopulos et al.
patent: 2002/0054896 (2002-05-01), Studin
patent: 2003/0078517 (2003-04-01), Kensey
patent: 2003/0084912 (2003-05-01), Pera
patent: 2003/0087962 (2003-05-01), Demopulos et al.
patent: 2003/0096807 (2003-05-01), Demopulos et al.
patent: 2003/0130165 (2003-07-01), Reitz et al.
patent: 2003/0138503 (2003-07-01), Staniforth et al.
patent: 2003/0158112 (2003-08-01), Campochiaro
patent: 2003/0235589 (2003-12-01), Demopulos et al.
patent: 2004/0132737 (2004-07-01), Cormier et al.
patent: 2004/0204355 (2004-10-01), Tracey et al.
patent: 2005/0021092 (2005-01-01), Yun et al.
patent: 2005/0069518 (2005-03-01), Mousa et al.
patent: 2005/0075702 (2005-04-01), Shafer
patent: 409219 (2005-06-01), None
patent: 3645036 (1999-01-01), None
patent: WO 97/34605 (1997-09-01), None
patent: WO 98/35699 (1998-08-01), None
patent: WO 99/35131 (1999-07-01), None
patent: 00/23062 (2000-04-01), None
patent: WO 00/23062 (2000-04-01), None
Moffett, et al. (1998). “Increased tyrosine phosphorylation and novelcis-acting element mediate activation of the fibroblast growth factor-2 (FGF-2) gene by nicotinic acetylcholine receptor. New mechanism for trans-synaptic regulation of cellular development and plasticity”,Molecular Brain Res., vol. 55: 293-305.
Møller, et al. (2002) “Effect of preoperative smoking intervention on postoperative complications: A randomized clinical trial”,Lancet, vol. 359: 144-117.
Pullan, et al (1994) “Transdermal nicotine for active ulcerative colitis”,New England Journal of Medicine, vol. 330: 811-815.
Sandborn (1999). “Nicotine therapy for ulcerative colitis: A review of rationale, mechanisms, pharmacology, and clinical results”,American J. of Gastroenterology, vol. 94(5): 1161-1171.
Scheid, et al. “Nicotine patches for aphthous ulcers due to Behcet's syndrome”,New England Journal of Medicine, 2000343:1816-1817.
Tonnesen, et al. (1991) “A double-blind trial of a 16-hour transdermal nicotine patche in smoking cessation”,New England Journal of Medicine, 325:311-315.
Usuki, et al. (1998) “Effects of nicotine on peripheral cutaneous blood flow and skin temperature”,J. Dermatol. Sci., vol. 16: 173-181.
Vieregge, et al. “Transdermal nicotine in PD: a randomized, double-blind, placebo controlled study”,Neurology2001, 57:1032-1035.
Villablanca (1998). “Nicotine stimulates DNA synthesis and proliferation in vascular endothelial cells in vitro”,American Physiological Society, pp. 2089-2098.
Volm, et al. (1999). “Angiogenesis and cigarette smoking in squamous cell lung carcinomas: an Immunohistochemical study of 28 cases”Anticancer Research, vol. 19: 333-336.
Westerman, et al. (1993) “The role of skin nociceptive afferent nerves in blister healing”,Clinical and Experimental Neurology, vol. 30: 39-60.
Yancopoulos, et al. (1998). “Vasculogenesis, angiogenesis, and growth factors: Ephrins enter the fray at the border”Cell, vol. 93: 661-664.
Heeschen, Christopher et al., “Nicotine is an agent of angiogenesis: Role of nitric oxide and prostacyclin” Journal of American College Cardiology, vol. 35, No. 2, Suppl. A, Feb. 2000, pp. 545A-546A XP001180280, 29thAnnual Scientific Session of the American College of Cardiology, Anaheim, CA, USA, Mar. 12-15, 2000, ISSN: 0735-1097.
Hannan, Robert L. et al. “Endothelial cells synthesize basic fibroblast growth factor and transforming growth factor beta”, Growth Factors, 1998, vol. 1, pp. 7-17.
Edelman, Elazer R. et al.“Basic Fibroblast Growth Factor Enhances the Coupling of Intimal Hyperplasia and Proliferation of Vasa Vasorum in Injured Rat Arteries”, J. Clin. Invest., vol. 89, Feb. 1992, pp. 465-473.
Ribatti, Domenico et al. “Human Neuroblastoma Cells Produce Extracellular Matrix-Degrading Enzymes, Induce Endothelial Cell Proliferation and are Angiogenic In Vivo”, Int. J. Cancer: 77, 449-454 (1998).
Hyman, Ph.D., Leslie et al. “Hypertension, Cardiovascular Disease, and Age-Related Macular Degeneration” Arch Opthamol, vol. 118, Mar. 2000.
Cucina et al. (1999) “Nicotine regulates basic fibroblastic growth factor and transforming growth factor β1 production in endothelial cells,” Biochem. Biophys Res Commun 257: 302-12.
Mousa and Mousa, “Cellular and Molecular Mechanisms of Nicotine's Pro-Angiogenesis Activity and Its Potential Impact on Cancer”, Journal of Cellular Biochemistry 97:1370-1378 (2006).
Belluardo, et al. (1998). “Acute intermittent nicotine treatment produces regional increases of basic fibroblast growth factor messenger RNA and protein in the tel-and diencephalon of the rat”,Neuroscience, vol. 83(3): 723-740.
Bornmyr, et al. (1991) “Thermography and laser—Doppler flowmetry for monitoring changes in finger skin blood flow upon cigarette smoking”,Clinical Physiology, vol. 11: 135-141.
Carty, et al. (1996). “Nicotine and cotinine stimulate secretion of basic fibroblast growth factor and affect expression of matrix metalloproteinases in cultured human smooth muscle cells”,J. of Vascular Surgery, vol. 24(6): 927-934.
Damaj, et al. (1998). “Antinociceptive responses to nicotinic acetylcholine receptor ligands after systemic and intrathecal administration in mice”,J. of Pharmacology and Experimental Therapeutics, vol. 284(3): 1058-1065.
Decker, et al. (1999) “Therapeutic potential of neuronal nicotinic acetylcholine receptor agonists as novel analgesics”,Biochem. Pharm., vol. 58: 917-923.
Folkman, et al. (1996). “Blood vessel formation: What is its molecular basis?”,Cell, vol. 87: 1153-1155.
Grando, et al. (1995) “A nicotinic acetylcholine receptor regulating cell adhesion and motility is expressed in human keratinocytes”,J. Invest. Dermatol., vol. 105: 774-781.
Grando, et al. (1996) “Activation of keratinocyte nicotinic cholinergic receptors stimulates calcium influx and enhances cell differentiation”,J. Invest. Dermatol., vol. 107: 412-418.
Grando, et al. (2000) “Nicotine and Pemphigus”,Arch Dermatol, 136:1269.
Haas, et al. (1992) “Jean Nicot 1530-1600”,J. Neurol. Neurosurg. Psychiatry, vol. 55: 430.
Hanahan et al. (1996). “Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis”,Cell, vol. 86: 353-364.
Kanekura, et al. “Successful treatment of pyoderma gangrenosum with nicotine chewing gum”,Letters to the Editor, pp. 704-705, J of Dermatology (1995); vol. 22.
Kanekura, et al. (1995) &#x
Cooke John
Heeschen Christopher
Jang James
Tsao Phillip
Borden Paula A.
Bozicevic Field & Francis LLP
Flood Michele C.
The Board of Trustees of the Leland Stanford Junior University
LandOfFree
Nicotine in therapeutic angiogenesis and vasculogenesis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nicotine in therapeutic angiogenesis and vasculogenesis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nicotine in therapeutic angiogenesis and vasculogenesis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4078623